OS Therapies Says Lung Cancer Therapy Meets Primary Endpoint in Phase 2 Study

MT Newswires Live

Jan 15, 2025

OS Therapies (OSTX) said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.

The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.

It added that all patients who reached the 12-month event-free survival endpoint remained alive.

"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication," Paul Romness, MHP, Chair & CEO of OS Therapies, said.

Shares of the company rose more than 60% in premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503364642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503364642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503364642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503364642","market":"sg","top_or_hot":-1,"title":"OS Therapies Says Lung Cancer Therapy Meets Primary Endpoint in Phase 2 Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> (OSTX) said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.</p><p>The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.</p><p>It added that all patients who reached the 12-month event-free survival endpoint remained alive.</p><p>\"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication,\" Paul Romness, MHP, Chair &amp; CEO of OS Therapies, said.</p><p>Shares of the company rose more than 60% in premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies Says Lung Cancer Therapy Meets Primary Endpoint in Phase 2 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies Says Lung Cancer Therapy Meets Primary Endpoint in Phase 2 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-15 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> (OSTX) said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.</p><p>The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.</p><p>It added that all patients who reached the 12-month event-free survival endpoint remained alive.</p><p>\"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication,\" Paul Romness, MHP, Chair &amp; CEO of OS Therapies, said.</p><p>Shares of the company rose more than 60% in premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSTX","symbol_name":"OS Therapies","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503364642","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503364642","pubTimestamp":1736948150,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OS Therapies  said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.It added that all patients who reached the 12-month event-free survival endpoint remained alive.\"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication,\" Paul Romness, MHP, Chair & CEO of OS Therapies, said.Shares of the company rose more than 60% in premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OSTX":"OS Therapies","BK4139":"生物科技"},"translate_title":"OS Therapies表示肺癌治疗在2期研究中达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":1},"content_text":"OS Therapies (OSTX) said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.It added that all patients who reached the 12-month event-free survival endpoint remained alive.\"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication,\" Paul Romness, MHP, Chair & CEO of OS Therapies, said.Shares of the company rose more than 60% in premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}